911860
NanoFabTx™ microfluidic - micro
device kit for synthesis of 1-5 μm particles
Synonyme(s) :
Microfluidic kit, Microparticle, NanoFabTx™ device kit, Nanoformulation
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
NACRES:
NA.23
UNSPSC Code:
12162002
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderdescription
Microfludic device kit for synthesizing 1-5 μm microparticles
Kit components :
Quality Level
application(s)
advanced drug delivery
General description
NanoFabTx™ Microfluidic - micro device kit includes a comprehensive protocol, pre-assembled microfluidic chip manifold, tubing, and accessories—a microfluidic platform to synthesize drug-encapsulating microparticles 1-5 μm in size. It is compatible with either a standard syringe pump (not included) or the Dolomite microfluidics system (not included). The device kit does not include reagents. NanoFabTx™- micro reagent kits, like NanoFabTx™ PLGA-micro (Cat.No. 912220) provide the reagents for the synthesis of 1-5 μm PLGA microparticles.
Application
NanoFabTx™ Microfluidic - micro device kit is designed to work with the NanoFabTx™- micro reagent kits for the synthesis of 1-5 μm particles (Cat.No. 912220) and can be used to create drug-encapsulated polymeric microspheres with narrow size-dispersity and consistent drug loading. Polymeric microparticles also can encapsulate larger biologics like proteins, mRNA, and DNA, in addition to drugs and small molecules, and may serve as vehicles for targeted delivery and controlled release. Microfluidic-based synthesis is a powerful tool in drug development for fabricating size-controlled drug-delivery particles, enabling scalable synthesis of particles and rapid formulation screening. In contrast to nanoprecipitation or solvent-displacement methods, microfluidic technologies have several advantages including enhanced reproducibility, less consumption of expensive reagents, and superior scalability.
Features and Benefits
- Step-by-step microfluidic-based protocols developed and tested by our formulation scientists
- Optimized to make monodisperse microparticles of any size between 1 and 5 μm
- Facilitates simple optimization of drug encapsulation and loading efficiency in microparticles
Legal Information
NANOFABTX is a trademark of Sigma-Aldrich Co. LLC
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Articles
Professor Robert K. Prud’homme introduces flash nanoprecipitation (FNP) for nanoparticle fabrication, which is a scalable, rapid mixing process for nanoparticle formulations.
Microfluidic assembly improves polyamine nanoencapsulation of nucleic acids, overcoming challenges like polydispersity and poor reproducibility.
NanoFabTx™ platform accelerates drug development with ready-to-use formulations and microfluidic devices for particle synthesis.
Contenu apparenté
Andrew Gdowski et al.
Journal of nanobiotechnology, 16(1), 12-12 (2018-02-13)
The process of optimization and fabrication of nanoparticle synthesis for preclinical studies can be challenging and time consuming. Traditional small scale laboratory synthesis techniques suffer from batch to batch variability. Additionally, the parameters used in the original formulation must be
Xuanyu Li et al.
Advanced drug delivery reviews, 128, 101-114 (2017-12-27)
Microfluidic chips allow the rapid production of a library of nanoparticles (NPs) with distinct properties by changing the precursors and the flow rates, significantly decreasing the time for screening optimal formulation as carriers for drug delivery compared to conventional methods.
Samar Damiati et al.
Genes, 9(2) (2018-02-22)
Microfluidic devices present unique advantages for the development of efficient drug carrier particles, cell-free protein synthesis systems, and rapid techniques for direct drug screening. Compared to bulk methods, by efficiently controlling the geometries of the fabricated chip and the flow
Numéro d'article de commerce international
| Référence | GTIN |
|---|---|
| 911860-1EA | 04061841359371 |